FDA
-
-
-
-
-
-
-
Lifeward Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
-
-
-
-
-
-
-
Lifeward Announces Reverse Share Split
-
-
-
-
-
-
-
Lifeward Appoints Bob Marshall as Chairman of the Board
-
-
-
-
-
-
-
Lifeward receives European approval for ReWalk 7 exoskeleton
-
-
-
-
-
-
-
MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion
-
-
-
-
-
-
-
Paralyzed Israeli Soldier Walks Again with Use of the ReWalk Personal Exoskeleton
-
325,297 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

